Mechanisms of Resistance to Antibody-Drug Conjugates

Antibody-drug conjugates (ADCs), with antibodies targeted against specific antigens linked to cytotoxic payloads, offer the opportunity for a more specific delivery of chemotherapy and other bioactive payloads to minimize side effects. First approved in the setting of HER2+ breast cancer, more recen...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2023-02, Vol.15 (4), p.1278
Main Authors: Abelman, Rachel Occhiogrosso, Wu, Bogang, Spring, Laura M, Ellisen, Leif W, Bardia, Aditya
Format: Article
Language:English
Subjects:
Antibodies
Antibody-drug conjugates
Antigens
Breast cancer
Cancer
Cancer therapies
Chemotherapy
Cytotoxicity
Dosage and administration
Drug resistance
ErbB-2 protein
FDA approval
Malignancy
Metastasis
Oncology, Experimental
Patients
Review
Side effects
Success
Surgery
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Antibody-drug conjugates (ADCs), with antibodies targeted against specific antigens linked to cytotoxic payloads, offer the opportunity for a more specific delivery of chemotherapy and other bioactive payloads to minimize side effects. First approved in the setting of HER2+ breast cancer, more recent ADCs have been developed for triple-negative breast cancer (TNBC) and, most recently, hormone receptor-positive (HR+) breast cancer. While antibody-drug conjugates have compared favorably against traditional chemotherapy in some settings, patients eventually progress on these therapies and require a change in treatment. Mechanisms to explain the resistance to ADCs are highly sought after, in hopes of developing next-line treatment options and expanding the therapeutic windows of existing therapies. These resistance mechanisms are categorized as follows: change in antigen expression, change in ADC processing and resistance, and efflux of the ADC payload. This paper reviews the recently published literature on these mechanisms as well as potential options to overcome these barriers.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers15041278